A randomized, double blind, biomarker selected, phase II clinical trial of maintenance PARP inhibition following chemotherapy for metastatic urothelial carcinoma (mUC): Final analysis of the ATLANTIS rucaparib arm.

Category Primary study
JournalJOURNAL OF CLINICAL ONCOLOGY
Year 2022
This article has no abstract
Epistemonikos ID: 85b3b464a9944d67b98b3249942495121c439082
First added on: Feb 14, 2025